Single Agent Samba? Doublet Dance? Mambo Combo? Mastering the Rhythm of Treatment Selection and Sequencing in Renal Cell Carcinoma – Tweetorial #2 Evaluation (ID: i810-5) Survey

Question Title

* 1. How many years have you been in practice?

>21

11-20

1-10

Question Title

* 2. How many patients with RCC do you manage per week?

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

Question Title

* 3. Please select the option that best describes your practice setting.

Academic medical center

Community hospital or medical center

VA, DOD, or other government

Managed care

Research

Pharmaceutical industry

Question Title

* 4. After participating in this activity, how confident are you in the management of patients with RCC in your practice?

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 5. How committed are you to making changes in your practice based on your participation in this activity?

Very committed

Committed

Neutral

Not committed

I do not plan to make changes

If not committed or do not plan to make changes, please indicate reason

Question Title

* 6. Which of the following best describes the impact of this activity on your performance?

I gained new strategies/skills/information I can apply to my area of practice

I need more information before I can change my practice

My practice is already consistent with the information presented

This activity will not change my practice

Question Title

* 7. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Have a better understanding of which treatment regimens are most beneficial for patient subsets

Carefully select patients for treatment with TKI/IO and IO/IO treatment regimens

Review of guideline recommendation prior to treatment selection

Question Title

* 8. What barriers do you see to making changes in your practice? Please select all that apply.

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement or legal issues

Conflicting guidelines or evidence

Patient compliance and/or patient resource barriers

Other (please explain)

Question Title

* 9. Please rate your level of agreement by checking the appropriate rating.

After participating in today’s activity, I am now better able to:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
ARTICULATE the rationale for synergistic efficacy between immuno-oncology therapies and antiangiogenic targeted treatments with their combined therapeutic applicability to advanced RCC	ARTICULATE the rationale for synergistic efficacy between immuno-oncology therapies and antiangiogenic targeted treatments with their combined therapeutic applicability to advanced RCC Strongly agree	ARTICULATE the rationale for synergistic efficacy between immuno-oncology therapies and antiangiogenic targeted treatments with their combined therapeutic applicability to advanced RCC Agree	ARTICULATE the rationale for synergistic efficacy between immuno-oncology therapies and antiangiogenic targeted treatments with their combined therapeutic applicability to advanced RCC Neutral	ARTICULATE the rationale for synergistic efficacy between immuno-oncology therapies and antiangiogenic targeted treatments with their combined therapeutic applicability to advanced RCC Disagree	ARTICULATE the rationale for synergistic efficacy between immuno-oncology therapies and antiangiogenic targeted treatments with their combined therapeutic applicability to advanced RCC Strongly disagree
COMPARE the efficacy and safety findings that emerged from phase 3 clinical trials supporting the approvals of combination strategies that are now embraced as the standard of care for treating advanced RCC in the first-line setting	COMPARE the efficacy and safety findings that emerged from phase 3 clinical trials supporting the approvals of combination strategies that are now embraced as the standard of care for treating advanced RCC in the first-line setting Strongly agree	COMPARE the efficacy and safety findings that emerged from phase 3 clinical trials supporting the approvals of combination strategies that are now embraced as the standard of care for treating advanced RCC in the first-line setting Agree	COMPARE the efficacy and safety findings that emerged from phase 3 clinical trials supporting the approvals of combination strategies that are now embraced as the standard of care for treating advanced RCC in the first-line setting Neutral	COMPARE the efficacy and safety findings that emerged from phase 3 clinical trials supporting the approvals of combination strategies that are now embraced as the standard of care for treating advanced RCC in the first-line setting Disagree	COMPARE the efficacy and safety findings that emerged from phase 3 clinical trials supporting the approvals of combination strategies that are now embraced as the standard of care for treating advanced RCC in the first-line setting Strongly disagree
EVALUATE combination therapies recommended by the most recent NCCN clinical practice guidelines as first-line treatments for your patients advanced RCC	EVALUATE combination therapies recommended by the most recent NCCN clinical practice guidelines as first-line treatments for your patients advanced RCC Strongly agree	EVALUATE combination therapies recommended by the most recent NCCN clinical practice guidelines as first-line treatments for your patients advanced RCC Agree	EVALUATE combination therapies recommended by the most recent NCCN clinical practice guidelines as first-line treatments for your patients advanced RCC Neutral	EVALUATE combination therapies recommended by the most recent NCCN clinical practice guidelines as first-line treatments for your patients advanced RCC Disagree	EVALUATE combination therapies recommended by the most recent NCCN clinical practice guidelines as first-line treatments for your patients advanced RCC Strongly disagree

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating.

Moshe C. Ornstein, MD, MA, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the Material	Presented the Material Strongly agree	Presented the Material Agree	Presented the Material Neutral	Presented the Material Disagree	Presented the Material Strongly disagree
Avoided Commercial Bias	Avoided Commercial Bias Strongly agree	Avoided Commercial Bias Agree	Avoided Commercial Bias Neutral	Avoided Commercial Bias Disagree	Avoided Commercial Bias Strongly disagree

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating.

Sumanta K. Pal, MD, FASCO, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the Material	Presented the Material Strongly agree	Presented the Material Agree	Presented the Material Neutral	Presented the Material Disagree	Presented the Material Strongly disagree
Avoided Commercial Bias	Avoided Commercial Bias Strongly agree	Avoided Commercial Bias Agree	Avoided Commercial Bias Neutral	Avoided Commercial Bias Disagree	Avoided Commercial Bias Strongly disagree

Question Title

* 12. Please rate your level of agreement by checking the appropriate rating.

Brian I. Rini, MD, FASCO, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the Material	Presented the Material Strongly agree	Presented the Material Agree	Presented the Material Neutral	Presented the Material Disagree	Presented the Material Strongly disagree
Avoided Commercial Bias	Avoided Commercial Bias Strongly agree	Avoided Commercial Bias Agree	Avoided Commercial Bias Neutral	Avoided Commercial Bias Disagree	Avoided Commercial Bias Strongly disagree

Question Title

* 13. The content presented: 

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Enhanced my current knowledge base	Enhanced my current knowledge base Strongly agree	Enhanced my current knowledge base Agree	Enhanced my current knowledge base Neutral	Enhanced my current knowledge base Disagree	Enhanced my current knowledge base Strongly disagree
Addressed my most pressing questions	Addressed my most pressing questions Strongly agree	Addressed my most pressing questions Agree	Addressed my most pressing questions Neutral	Addressed my most pressing questions Disagree	Addressed my most pressing questions Strongly disagree
Promoted improvements or quality in health care	Promoted improvements or quality in health care Strongly agree	Promoted improvements or quality in health care Agree	Promoted improvements or quality in health care Neutral	Promoted improvements or quality in health care Disagree	Promoted improvements or quality in health care Strongly disagree
Was scientifically rigorous and evidence based	Was scientifically rigorous and evidence based Strongly agree	Was scientifically rigorous and evidence based Agree	Was scientifically rigorous and evidence based Neutral	Was scientifically rigorous and evidence based Disagree	Was scientifically rigorous and evidence based Strongly disagree
Avoided commercial bias or influence	Avoided commercial bias or influence Strongly agree	Avoided commercial bias or influence Agree	Avoided commercial bias or influence Neutral	Avoided commercial bias or influence Disagree	Avoided commercial bias or influence Strongly disagree

Single Agent Samba? Doublet Dance? Mambo Combo? Mastering the Rhythm of Treatment Selection and Sequencing in Renal Cell Carcinoma – Tweetorial #2 Evaluation (ID: i810-5)

Question Title

* 1. How many years have you been in practice?

Question Title

* 2. How many patients with RCC do you manage per week?

Question Title

* 3. Please select the option that best describes your practice setting.

Question Title

* 4. After participating in this activity, how confident are you in the management of patients with RCC in your practice?

Question Title

* 5. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 6. Which of the following best describes the impact of this activity on your performance?

Question Title

* 7. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Question Title

* 8. What barriers do you see to making changes in your practice? Please select all that apply.

Question Title

* 9. Please rate your level of agreement by checking the appropriate rating.

After participating in today’s activity, I am now better able to:

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating.

Moshe C. Ornstein, MD, MA, effectively:

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating.

Sumanta K. Pal, MD, FASCO, effectively:

Question Title

* 12. Please rate your level of agreement by checking the appropriate rating.

Brian I. Rini, MD, FASCO, effectively:

Question Title

* 13. The content presented:

Question Title

* 14. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 15. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for RCC

Question Title

* 16. If you indicated that you perceived commercial bias or influence, please describe.

Question Title

* 1. How many years have you been in practice?

Question Title

* 2. How many patients with RCC do you manage per week?

Question Title

* 3. Please select the option that best describes your practice setting.

Question Title

* 4. After participating in this activity, how confident are you in the management of patients with RCC in your practice?

Question Title

* 5. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 6. Which of the following best describes the impact of this activity on your performance?

Question Title

* 7. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Question Title

* 8. What barriers do you see to making changes in your practice? Please select all that apply.

Question Title

* 9. Please rate your level of agreement by checking the appropriate rating. After participating in today’s activity, I am now better able to:

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating. Moshe C. Ornstein, MD, MA​, effectively:

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating. Sumanta K. Pal, MD, FASCO, effectively:

Question Title

* 12. Please rate your level of agreement by checking the appropriate rating. Brian I. Rini, MD, FASCO, effectively:

Question Title

* 13. The content presented:

Question Title

* 14. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 15. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for RCC

Question Title

* 16. If you indicated that you perceived commercial bias or influence, please describe.

* 9. Please rate your level of agreement by checking the appropriate rating.

After participating in today’s activity, I am now better able to:

* 10. Please rate your level of agreement by checking the appropriate rating.

Moshe C. Ornstein, MD, MA, effectively:

* 11. Please rate your level of agreement by checking the appropriate rating.

Sumanta K. Pal, MD, FASCO, effectively:

* 12. Please rate your level of agreement by checking the appropriate rating.

Brian I. Rini, MD, FASCO, effectively:

* 13. The content presented: 